TARRYTOWN, N.Y., Sept. 13 /PRNewswire-FirstCall/ — Regeneron
Pharmaceuticals, Inc. (Nasdaq:
REGN) will webcast its presentation at the UBS Global Life
Sciences Conference on Monday, September 20, 2010. The
presentation is scheduled for 10:00 a.m. Eastern Time. The
session may be accessed through the Company’s web site, www.regeneron.com, on the
Investor Relations page. An archived version of the
presentation will be available after the live webcast through
October 20, 2010.
Regeneron is a fully integrated biopharmaceutical company that
discovers, develops, and commercializes medicines for the treatment
of serious medical conditions. In addition to ARCALYST®
(rilonacept) Injection for Subcutaneous Use, its first
commercialized product, Regeneron has therapeutic candidates in
Phase 3 clinical trials for the potential treatment of gout,
diseases of the eye (wet age-related macular degeneration and
central retinal vein occlusion), and certain cancers.
Additional therapeutic candidates developed from proprietary
Regeneron technologies for creating fully human monoclonal
antibodies are in earlier stage development programs in rheumatoid
arthritis and other inflammatory conditions, pain, cholesterol
reduction, allergic and immune conditions and cancer.
Additional information about Regeneron and recent news
releases are available on Regeneron’s web site at www.regeneron.com. Contact
Information:Michael Aberman, M.D.Investor Relations914.345.7799
michael.aberman@regeneron.comPeter DworkinCorporate
Communications914.345.7800
peter.dworkin@regeneron.com
‘/>”/>
SOURCE
